Molekulares POCT: Wegbereiter einer neuen Ära der Sofortdiagnostik

In the rapidly evolving landscape of medical technology, Molecular Point-of-Care Testing (POCT) is emerging as a shining star in the field of medical diagnostics. By integrating nucleic acid extraction, amplification, and detection into a single, closed, and portable device, Molecular POCT has simplified the diagnostic process while effectively minimizing the risk of sample contamination. This innovative approach promises faster and more accurate diagnostic capabilities.

Technical Principles: A Perfect Blend of Miniaturization and High Efficiency

The core technologies of Molecular POCT include real-time fluorescent PCR (qPCR) and Loop-Mediated Isothermal Amplification (LAMPE). qPCR, known for its high sensitivity and specificity, is widely used in infectious disease detection, such as screening for COVID-19, influenza, and tuberculosis. LAMPE, auf der anderen Seite, requires no complex thermal cycling equipment, making it a fast and suitable option for primary healthcare settings. Zusätzlich, the latest research has combined microfluidic chips with CRISPR/Cas12a technology, enabling physical separation of the isothermal amplification and detection processes, thereby further enhancing sensitivity and accuracy.

Anwendungsszenarien: Comprehensive Coverage from Hospitals to Homes

The applications of Molecular POCT are incredibly diverse, spanning emergency departments in hospitals, primary healthcare units, and home health monitoring. In ICU wards, Molecular POCT can rapidly provide diagnostic results, buying valuable time for critically ill patients. In outpatient and emergency laboratories, its modular design and on-demand testing capabilities meet the needs of patients requiring quick diagnostics. Darüber hinaus, Molecular POCT is widely used in community healthcare, health check-up centers, customs quarantine, and food safety testing.

Market Trends: High-Speed Growth Driven by Technological Innovation

In den letzten Jahren, the Molecular POCT market has experienced rapid growth. In 2023, the global sales of POCT molecular diagnostic technologies reached $5.683 billion, with projections indicating it will reach $10.128 Milliarden von 2030. In China, the market is also expanding swiftly, mit einem 2023 market size of $266 million, expected to grow to $711 million by 2030. As technology continues to advance and application scenarios expand, Molecular POCT is becoming an indispensable part of the medical diagnostics landscape.

Zukunftsausblick: Intelligent POCT Leading the Way in Healthcare

With the integration of emerging technologies such as artificial intelligence and the Internet of Things, Molecular POCT is poised to become even smarter and more precise. These devices will not only enable remote operation and data sharing but also provide support for medical decision-making through cloud-based platforms. From epidemic control to chronic disease management, from community healthcare to home health monitoring, the future of Molecular POCT is bright, offering endless possibilities for human health.

Molekulares POCT, as a leading-edge representative of instantaneous diagnostic technology, is transforming the future of medical diagnostics with its efficiency, convenience, and accuracy.

Anbieter

Shanghai Lingjun Biotechnology Co., Ltd.wurde gegründet in 2016 Das ist ein professioneller Hersteller von biomagnetischen Materialien und Nukleinsäure-Extraktionsreagenzien.

Wir verfügen über umfangreiche Erfahrung in der Extraktion und Reinigung von Nukleinsäuren, Proteinreinigung, Zelltrennung, Chemilumineszenz, und anderen technischen Bereichen.

Unsere Produkte werden in vielen Bereichen weit verbreitet eingesetzt, wie zum Beispiel medizinische Tests, Gentests, universitäre Forschung, genetische Zucht, und so weiter. Wir liefern nicht nur Produkte, sondern können auch OEM übernehmen, ODM, und andere Bedürfnisse. Wenn Sie einen entsprechenden Bedarf haben, Nehmen Sie gerne Kontakt zu uns auf .